Clinical trials: Dermatitis Atopic
Atopic Dermatitis
Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood
This comparative study analyzes the efficacy and safety of treatment of children from 6 years of age suffering from moderate to severe atopic dermatitis using an inhibitor of IL4, IL13 and classical immunosuppressants.
- Trial name
- NCT04895423
- Testing
- Methotrexate therapy, Mycophenolate mofetil therapy, Cyclosporine therapy
- Where
- Russia
- Volunteers
- 160 people
- Sponsor
- National Medical Research Center for Children's Health, Russian Federation
Atopic Dermatitis, Eczema
The Role of Bathing Additives in the Treatment of Pediatric Atopic Dermatitis
To evaluate the efficacy of water bath, water + bleach, and water + vinegar (acetic acid) in the treatment of atopic dermatitis (eczema)
- Trial name
- ASPIRE (NCT03775590)
- Testing
- Water, Bleach, Acetic acid
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Eczema, Atopic Dermatitis
Bleach vs. Bubbles: Assessing the Impact of the Bathroom Environment on Eczema
Purpose: Evaluate the impact of cleaning the bathroom environment on the severity of eczema. Determine if part of the efficacy of bleach baths may be in cleaning the bathroom.
- Conditions
- Eczema, Atopic Dermatitis, Atopic Dermatitis and Related Conditions
- Trial name
- NCT03619161
- Testing
- Bubbles, Bleach and Bubbles
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- University of North Carolina, Chapel Hill
Atopic Dermatitis
A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in participants with moderate-to-severe atopic dermatitis.
- Trial name
- NCT03443024
- Testing
- Lebrikizumab
- Where
- 58 sites in United States
- Volunteers
- 280 people
- Sponsor
- Eli Lilly and Company
Dermatitis, Atopic, Eczema, Atopic
Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis
The overall aim of this study is to assess the effects of a new treatment called Secukinumab in adults suffering from moderate to severe atopic dermatitis.
- Conditions
- Dermatitis, Atopic, Eczema, Atopic, Neurodermatitis, Atopic
- Trial name
- Secu_in_AD (NCT03568136)
- Testing
- Secukinumab 300 mg
- Where
- 5 sites in Germany
- Volunteers
- 22 people
- Sponsor
- GWT-TUD GmbH
Atopic Dermatitis
Investigating Immune Mechanisms in Atopic Eczema
The aim of this study is to investigate the mechanisms behind the immune dysfunction that occurs in atopic eczema (or atopic dermatitis).
- Trial name
- NCT02102841
- Testing
- Skin biopsy, Skin suction blister, Mantoux test
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- University College, London
Atopic Dermatitis
Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD
This is a Phase 2 randomized, double-blind, parallel group, vehicle-controlled study to evaluate the safety and efficacy of topical ATx201 OINTMENT in adolescents and adults with mild to moderate Atopic Dermatitis
- Trial name
- NCT04339985
- Testing
- ATx201, ATx201 OINTMENT vehicle
- Where
- 10 sites in Bulgaria, Denmark and 1 more
- Volunteers
- 220 people
- Sponsor
- UNION therapeutics
Atopic Dermatitis
Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period
This trial is a single-center two arm, open label observational prospective study, that will evaluate the safety and efficacy of crisaborole ointment, 2% alone compared to a combination therapy of crisaborole and a topical…
- Trial name
- NCT04008784
- Testing
- Crisaborole 2% Topical Application Ointment [EUCRISA], Triamcinolone Acetonide 0.1% Ointment
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Clinical Research Center of the Carolinas
Atopic Dermatitis, Atopic Eczema
The Effects of Topical Corticosteroid Use on Insulin Sensitivity and Bone Turnover
The investigators believe that the emerging epidemiological evidence connecting topical use of corticosteroids to the development of type 2 diabetes and osteoporosis point to potentially massive, yet clinically unacknowledged…
- Trial name
- NCT04114097
- Testing
- Protopic, tacrolimus ointment 0.1%
- Where
- Denmark
- Volunteers
- 36 people
- Sponsor
- Jacob Thyssen
Atopic Dermatitis
Study of the Skin Microbiome and the Potential of a Topical Probiotic Cream for Atopic Dermatitis
The skin microbiome of atopic dermatitis patients and healthy volunteers will be studies by collecting and analysing skin swabs on different timepoint.
- Trial name
- NCT04771910
- Testing
- Topical cream with live probiotic bacteria
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Hospital, Antwerp
Atopic Dermatitis
An Open-Labeled Exploratory Study to Evaluate Safety and Efficacy of FB825 in Adults With Atopic Dermatitis
The purpose of this study is to evaluate the Safety and Efficacy of FB825 in Adults with Atopic Dermatitis
- Trial name
- NCT03758716
- Testing
- FB825, FB825-15D11, Anti-CemX
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- Fountain Biopharma Inc.
Atopic Dermatitis
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis
The purpose of the study is to explore the efficacy and safety of SUN13834 vs placebo in adult participants with atopic dermatitis.
- Trial name
- NCT00717769
- Testing
- SUN13834
- Where
- 28 sites in United States
- Volunteers
- 270 people
- Sponsor
- Daiichi Sankyo
Dermatitis, Atopic
Atopic Dermatitis in Atopy Predisposed Infants
The primary objective of this study is to investigate the effectiveness of a standardized skin care regimen using a milk lotion once daily and a bathing addendum as needed during the first 52 weeks of life on the development of…
- Trial name
- ADAPI (NCT02906475)
- Testing
- standardized skin care regimen
- Where
- Germany
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- HiPP GmbH & Co. Vertrieb KG
Atopic Dermatitis
A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis
The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).
- Trial name
- ADmIRe (NCT03831191)
- Testing
- LY3375880
- Where
- 58 sites in United States, Argentina and 11 more
- Volunteers
- 136 people
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis, Pruritus
Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone
To study the etiology and the epigenetic pathways leading to and regulating chronic itch. Similarly, to examine the mechanisms underlying skin changes, including epigenetic alterations while also testing the efficacy of…
- Conditions
- Atopic Dermatitis, Pruritus, Dermatitis
- Trial name
- NCT04154033
- Testing
- Naltrexone
- Where
- United States
- Sponsor
- University of Minnesota
Hidradenitis Suppurativa, Dermatitis, Atopic
Evaluation of Cutaneous and Circulating Inflammatory Biomarkers in Hidradenitis Suppurativa and Atopic Dermatitis
This non-intervention study will identify the biomarker profiles in hidradenitis suppurativa (HS) and atopic dermatitis (AD) (as a comparator) that would have the most utility in interventional studies evaluating efficacy during…
- Trial name
- NCT04440410
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Kymera Therapeutics, Inc.
Atopic Dermatitis
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
The purpose of this study is to establish the efficacy of each strength of ruxolitinib cream once daily (QD) or twice daily (BID) in participants with atopic dermatitis as compared with vehicle cream BID.
- Trial name
- NCT03011892
- Testing
- Ruxolitinib 0.15% Cream QD, Ruxolitinib 0.5% Cream QD, Ruxolitinib 1.5% Cream QD
- Where
- 52 sites in United States, Canada
- Volunteers
- 307 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis (AD)
A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil
Atopic Dermatitis (AD) is a chronic inflammatory skin disease that is characterized by intense itching, oozing and crusting, redness, skin erosion and dry skin.
- Trial name
- NCT04666675
- Testing
- Upadacitinib
- Sponsor
- AbbVie
Quality of Life, Atopic Dermatitis
Assessment of the Impact of Whole Body Cryostimulation on Skin Physiological Indicators
The aim of the planned study will be to evaluate the effect of repeated cryostimulation treatments on immunological, morphological, and biochemical indicators of the peripheral blood of patients with atopic dermatitis (AD).
- Trial name
- NCT03761199
- Testing
- whole body cryostimulation
- Where
- Poland
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University School of Physical Education, Krakow, Poland
Atopic Dermatitis
Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis
This study is being conducted to provide data on efficacy, safety, tolerability and PK of multiple topical formulation concentrations of PF-06700841 topical cream in the treatment of mild to moderate atopic dermatitis (AD).
- Trial name
- NCT03903822
- Testing
- PF-06700841
- Where
- 76 sites in United States, Australia and 8 more
- Volunteers
- 292 people
- Sponsor
- Pfizer